BioSpace News Archive

— Completed last patient visits in Phase 3 PFIC and Phase 2 NASH Trials — — Enrolled first biliary atresia patients in second odevixibat pivotal study — — Completed two financing transactions to secure cash into beginning of 2022 — — Management to host conference call and webcast today at 10:00 a.m. ET — BOSTON, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today pro

Cabaletta Bio, Inc., a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, announced financial results for the second quarter ended June 30, 2020 and provided a business update.

The global Phase 2/3 study with opaganib is set to enroll up to 270 patients with severe COVID-19 across 40 clinical sites

InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, will present at several upcoming virtual investor events in August and September as follows: BTIG Virtual Biotechnology Conference: August 10 th – 11 th A BTIG analyst will host a fireside chat with Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, to discuss the Com

Helius Medical Technologies, Inc., a neurotech company focused on neurological wellness, announced that it has submitted a request to the U.S. Food and Drug Administration for de novo classification and clearance of the Portable Neuromodulation Stimulator device and reported preliminary financial results for the second quarter and six months ended June 30, 2020.

Narrowed 2020 Full-Year Revenue and Adjusted EBITDA (non-GAAP) Guidance Ranges Primarily Due to the Impact of COVID-19 Pandemic

- On track to report three significant data readouts in next few months - - Completes successful financings, raising gross proceeds of $13.4 million; sufficient to reach multiple important milestones - - Management to hold conference call today, August 6, at 10:00 am EDT - [06-August-2020] TEL AVIV, Israel , Aug. 6, 2020 /PRNewswire/ -- Bi

CANTEL MEDICAL CORP. announced an estimated revenue range for the company’s fiscal fourth quarter, which ended July 31st, 2020.

Sierra Oncology, Inc.today reported its financial and operational results for the second quarter ended June 30, 2020.

Sierra Oncology, Inc. announced the appointments of Mr. Kevin Norrett as Chief Business Officer and Mr. William D. Turner as Chief Regulatory and Technical Operations Officer.